HCWB
HCW Biologics Inc. NASDAQ$0.45
Mkt Cap $948,160
52w Low $0.25
1.2% of range
52w High $17.80
50d MA $0.50
200d MA $2.41
P/E (TTM)
-0.0x
EV/EBITDA
-1.2x
P/B
0.3x
Debt/Equity
2.5x
ROE
-287.9%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
0.91
50d MA
$0.50
200d MA
$2.41
Avg Volume
9.0M
About
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.84 | -2.63 | -213.1% | 0.36 | -8.3% | -16.7% | -25.6% | -20.2% | -24.2% | -8.8% | +30.9% | — |
| Nov 14, 2025 | AMC | 1.58 | -2.02 | -227.8% | 3.00 | +0.7% | +2.0% | -19.7% | -33.3% | -36.0% | -27.7% | -37.7% | — |
| Aug 18, 2025 | AMC | 1.80 | -6.79 | -477.2% | 4.02 | -10.0% | -11.4% | -15.4% | -17.7% | -14.2% | +38.1% | +7.2% | — |
| May 15, 2025 | AMC | — | -0.05 | — | 8.20 | +0.0% | +9.1% | +4.5% | +12.0% | +6.1% | +1.3% | -34.8% | — |
| Mar 28, 2025 | AMC | 3.60 | -3.20 | -188.9% | 12.00 | -5.7% | -6.0% | -6.3% | -6.1% | -20.4% | -24.2% | -38.3% | — |
| Nov 14, 2024 | AMC | -5.20 | -4.00 | +23.1% | 12.36 | -8.4% | -4.7% | +301.3% | +256.0% | +206.6% | +129.6% | +15.2% | — |
| Aug 14, 2024 | AMC | -7.20 | -16.00 | -122.2% | 23.20 | -13.8% | -13.6% | -13.8% | -13.8% | -23.3% | -26.0% | +5.2% | — |
| May 15, 2024 | AMC | — | -8.00 | — | 46.40 | -4.3% | -5.2% | -5.2% | -4.3% | -4.3% | -4.3% | -3.4% | — |
| Mar 26, 2024 | AMC | — | -0.15 | — | 68.00 | -4.1% | +3.5% | +2.9% | -2.9% | -2.4% | -2.4% | -14.1% | — |
| Nov 14, 2023 | AMC | -0.13 | -5.60 | -4207.7% | 46.40 | +0.0% | -20.7% | -8.6% | -5.6% | -6.9% | -6.0% | -1.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29 | Maxim Group | Maintains | Buy → Buy | — | $8.00 | $8.00 | +0.0% | +0.2% | -3.4% | -9.9% | -16.2% | -23.2% |
| Apr 19 | EF Hutton | Maintains | Buy → Buy | — | $59.60 | $58.40 | -2.0% | -2.0% | -8.1% | -7.0% | -5.0% | -6.4% |
| Mar 30 | EF Hutton | Maintains | Buy → Buy | — | $58.40 | $62.40 | +6.8% | -8.9% | -4.0% | -6.8% | -3.4% | -0.7% |
| Mar 23 | EF Hutton | Maintains | Buy → Buy | — | $54.00 | $60.80 | +12.6% | +7.4% | +3.0% | +1.1% | -1.5% | +8.1% |
| Nov 8 | JonesTrading | Maintains | Buy → Buy | — | $91.20 | $89.60 | -1.8% | -2.3% | +1.8% | -1.3% | -4.4% | -5.5% |
| Mar 24 | Maxim Group | Maintains | Buy → Buy | — | $91.20 | $96.40 | +5.7% | +3.9% | +13.2% | +5.7% | +7.9% | +10.5% |
| Nov 19 | EF Hutton | Maintains | Buy → Buy | — | $114.40 | $119.20 | +4.2% | +2.8% | -6.3% | -8.7% | -1.4% | -4.5% |
Recent Filings
8-K · 8.01
!! High
HCW Biologics Inc. -- 8-K 8.01: Material Event / Announcement
HCW Biologics failed to achieve quorum at its special stockholder meeting, preventing any votes on proposed matters and potentially delaying critical corporate actions.
Apr 30
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
HCWB amended its bylaws, likely reflecting internal governance changes that could affect shareholder rights, board procedures, or management structure—investors should review specific amendments for potential impacts on voting power or operational control.
Apr 16
8-K
Unknown — 8-K Filing
HCW Biologics reported Q4 2025 results as a clinical-stage biotech, meaning investors are betting on future drug approvals rather than current revenue, carrying significant execution and regulatory risk.
Mar 31
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
HCWB secured two exclusive licensing agreements worth $7.0 million, providing new revenue streams and potentially expanding its product portfolio, which could drive near-term growth and improve profitability margins.
Mar 17
8-K
HCW Biologics Inc. -- 8-K Filing
HCW Biologics faces imminent delisting from Nasdaq due to noncompliance with listing standards, with the exchange staff set to issue a Delist Determination Letter and the company unable to cure the deficiency.
Mar 2
8-K · 8.01
!! High
HCW Biologics Inc. -- 8-K 8.01: Material Event / Announcement
This 8-K filing by HCW Biologics (HCWB) contains only standard legal disclaimers about securities offerings, providing no material information about company events or business developments affecting investors.
Feb 19
8-K · 1.01
!! High
HCW Biologics Inc. -- 8-K 1.01: Material Agreement
HCW Biologics secured an exclusive worldwide license agreement with WY Biotech for HCW11-006's in vivo applications, generating upfront revenue and potential milestone payments plus a Greater China option.
Feb 13
Data updated apr 25, 2026 1:14pm
· Source: massive.com